Deep Sequencing of Protease Inhibitor Resistant HIV Patient Isolates Reveals Patterns of Correlated Mutations in Gag and Protease

PLoS Computational Biology

Volumn 11, Issue 4, 2015, Pages

  Flynn, William F ^a,b   Chang, Max W ^c   Tan, Zhiqiang ^d   Oliveira, Glenn ^c   Yuan, Jinyun ^c   Okulicz, Jason F ^e   Torbett, Bruce E ^c   Levy, Ronald M ^b,f  

^a RUTGERS UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d RUTGERS UNIVERSITY   (United States)

^e SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^f Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITION;

CO-VARIATIONS; DRUG-RESISTANCE; HIGH-PRECISION; HIV PATIENTS; HIV-PROTEASE; MATRIX; POLYPROTEINS; PROTEASE INHIBITOR; SEQUENCE COVERAGES; TIGHT BOUND;

DRUG THERAPY;

GAG PROTEIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEIN VP6; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ARTICLE; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE; MAJOR CLINICAL STUDY; MUTATION; NEXT GENERATION SEQUENCING; PROTEIN CLEAVAGE; PROTEIN FUNCTION; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD; VIRUS REPLICATION; ANTIVIRAL RESISTANCE; BIOLOGY; DRUG EFFECTS; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN IMMUNODEFICIENCY VIRUS 1; VIROLOGY;

MIRIDAE;

COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, VIRAL; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION;

EID: 84929497885     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1004249     Document Type: Article

References (66)

1. Johnson V a, Calvez V, Gunthard HF, Paredes R, Pillay D, et al. (2013) Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 21: 6–14. 23596273
2. Kutilek VD, Sheeter DA, Elder JH, Torbett BE, (2003) Is resistance futile? Curr drug targets Infect Disord 3: 295–309. 14754431
3. Rhee S-Y, Liu TF, Holmes SP, Shafer RW, (2007) HIV-1 subtype B protease and reverse transcriptase amino acid covariation. PLoS Comput Biol 3: e87. doi: 10.1371/journal.pcbi.0030087 17500586
4. Wu TD, Schiffer CA, Gonzales MJ, Taylor J, Kantor R, et al. (2003) Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments. J Virol 77: 4836–4847. doi: 10.1128/JVI.77.8.4836 12663790
5. Hoffman NG, Schiffer CA, Swanstrom R, (2003) Covariation of amino acid positions in HIV-1 protease. Virology 314: 536–548. doi: 10.1016/S0042-6822(03)00484-7 14554082
6. Fun A, Wensing AMJ, Verheyen J, Nijhuis M, (2012) Human Immunodeficiency Virus Gag and protease: partners in resistance. Retrovirology 9: 63. doi: 10.1186/1742-4690-9-63 22867298
7. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW, (2007) Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 17: 1195–1201. doi: 10.1101/gr.6468307 17600086
8. Banke S, Lillemark MR, Gerstoft J, Obel N, Jørgensen LB, (2009) Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations. J Virol 83: 8916–8924. doi: 10.1128/JVI.00003-09 19515784
9. Fischer W, Ganusov V V, Giorgi EE, Hraber PT, Keele BF, et al. (2010) Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One 5: e12303. doi: 10.1371/journal.pone.0012303 20808830
10. Hedskog C, Mild M, Jernberg J, Sherwood E, Bratt G, et al. (2010) Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS One 5: e11345. doi: 10.1371/journal.pone.0011345 20628644
11. Kagan RM, Cheung PK, Huard TK, Lewinski MA, (2006) Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment. Antiviral Res 71: 42–52. doi: 10.1016/j.antiviral.2006.02.008 16600392
12. Kolli M, Stawiski E, Chappey C, Schiffer CA, (2009) Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance. J Virol 83: 11027–11042. doi: 10.1128/JVI.00628-09 19706699
13. Kozísek M, Henke S, Sasková KG, Jacobs GB, Schuch A, et al. (2012) Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease. Antimicrob Agents Chemother 56: 4320–4330. doi: 10.1128/AAC.00465-12 22644035
14. Bally F, Martinez R, Peters S, Sudre P, (2000) Polymorphism of HIV Type 1 Gag p7/p1 and p1/p6 Cleavage Sites : Clinical Significance and Implications for Resistance to Protease Inhibitors. AIDS Res Hum Retroviruses 16: 1209–1213. 10957718
15. Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, et al. (2012) Detection of ultra-rare mutations by next-generation sequencing. PNAS 109: 14508–14513. 10.1073/pnas.1208715109/-/DCSupplemental. doi: 10.1073/pnas.1208715109 22853953
16. Shendure J, Ji H, (2008) Next-generation DNA sequencing. Nat Biotechnol 26: 1135–1145. doi: 10.1038/nbt1486 18846087
17. Macalalad AR, Zody MC, Charlebois P, Lennon NJ, Newman RM, et al. (2012) Highly sensitive and specific detection of rare variants in mixed viral populations from massively parallel sequence data. PLoS Comput Biol 8: e1002417. doi: 10.1371/journal.pcbi.1002417 22438797
18. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, et al. (2005) Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 43: 406–413. doi: 10.1128/JCM.43.1.406-413.2005 15635002
19. Liang B, Luo M, Scott-Herridge J, Semeniuk C, Mendoza M, et al. (2011) A comparison of parallel pyrosequencing and sanger clone-based sequencing and its impact on the characterization of the genetic diversity of HIV-1. PLoS One 6: e26745. doi: 10.1371/journal.pone.0026745 22039546
20. Malboeuf CM, Yang X, Charlebois P, Qu J, Berlin AM, et al. (2013) Complete viral RNA genome sequencing of ultra-low copy samples by sequence-independent amplification. Nucleic Acids Res 41: e13. doi: 10.1093/nar/gks794 22962364
21. Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R, (2011) Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci U S A 108: 20166–20171. doi: 10.1073/pnas.1110064108 22135472
22. Chang MW, Oliveira G, Yuan J, Okulicz JF, Levy S, et al. (2013) Rapid deep sequencing of patient-derived HIV with ion semiconductor technology. J Virol Methods 189: 232–234. doi: 10.1016/j.jviromet.2013.01.019 23384677
23. Gianella S, Delport W, Pacold ME, Young JA, Choi JY, et al. (2011) Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J Virol 85: 8359–8367. doi: 10.1128/JVI.02582-10 21632754
24. Shafer RW, (2006) Rationale and uses of a public HIV drug-resistance database. J Infect Dis 194 Suppl: S51–S58. doi: 10.1086/505356 16921473
25. Shafer RW, Rhee S-Y, Pillay D, Miller V, Sandstrom P, et al. (2007) HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 21: 215–223. doi: 10.1097/QAD.0b013e328011e691 17197813
26. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, et al. (2009) Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 4: e4724. doi: 10.1371/journal.pone.0004724 19266092
27. Haq O, Levy RM, Morozov A V, Andrec M, (2009) Pairwise and higher-order correlations among drug-resistance mutations in HIV-1 subtype B protease. BMC Bioinformatics 14: 1–14. doi: 10.1186/1471-2105-10-S8-S10
28. Li G, Verheyen J, Rhee S-Y, Voet A, Vandamme A-M, et al. (2013) Functional conservation of HIV-1 Gag: implications for rational drug design. Retrovirology 10: 126. doi: 10.1186/1742-4690-10-126 24176092
29. Rihn SJ, Wilson SJ, Loman NJ, Alim M, Bakker SE, et al. (2013) Extreme genetic fragility of the HIV-1 capsid. PLoS Pathog 9: e1003461. doi: 10.1371/journal.ppat.1003461 23818857
30. Gatanaga H, Suzuki Y, Tsang H, Yoshimura K, Kavlick MF, et al. (2002) Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J Biol Chem 277: 5952–5961. doi: 10.1074/jbc.M108005200 11741936
31. Nijhuis M, Wensing AMJ, Bierman WFW, de Jong D, Kagan R, et al. (2009) Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. J Infect Dis 200: 698–709. doi: 10.1086/605329 19627247
32. Kolli M, Ozen A, Kurt-Yilmaz N, Schiffer CA, (2014) HIV-1 Protease substrate co-evolution in Nelfinavir resistance. J Virol: JVI.00266–14 –. doi: 10.1128/JVI.00266-14
33. Knops E, Brakier-Gingras L, Schülter E, Pfister H, Kaiser R, et al. (2012) Mutational patterns in the frameshift-regulating site of HIV-1 selected by protease inhibitors. Med Microbiol Immunol 201: 213–218. doi: 10.1007/s00430-011-0224-z 22200908
34. Parry CM, Kolli M, Myers RE, Cane PA, Schiffer CA, et al. (2011) Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity. Antimicrob Agents Chemother 55: 1106–1113. doi: 10.1128/AAC.01228-10 21149628
35. Ganser-Pornillos BK, Yeager M, Sundquist WI, (2008) The structural biology of HIV assembly. Curr Opin Struct Biol 18: 203–217. doi: 10.1016/j.sbi.2008.02.001 18406133
36. Datta S a K, Curtis JE, Ratcliff W, Clark PK, Crist RM, et al. (2007) Conformation of the HIV-1 Gag protein in solution. J Mol Biol 365: 812–824. doi: 10.1016/j.jmb.2006.10.073 17097677
37. Ekeberg M, Lövkvist C, Lan Y, Weigt M, Aurell E, (2013) Improved contact prediction in proteins: Using pseudolikelihoods to infer Potts models. Phys Rev E 87: 012707. doi: 10.1103/PhysRevE.87.012707 23410359
38. Shekhar K, Ruberman C, Ferguson A, Barton J, Kardar M, et al. (2013) Spin models inferred from patient-derived viral sequence data faithfully describe HIV fitness landscapes. Phys Rev E 88: 062705. doi: 10.1103/PhysRevE.88.062705 24483484
39. Sharon D, Tilgner H, Grubert F, Snyder M, (2013) A single-molecule long-read survey of the human transcriptome. Nat Biotechnol 31: 1009–1014. doi: 10.1038/nbt.2705 24108091
40. Korber BT, Farber RM, Wolpert DH, Lapedes AS, (1993) Covariation of mutations in the V3 loop of human immunodeficiency virus type 1 envelope protein: an information theoretic analysis. Proc Natl Acad Sci U S A 90: 7176–7180. 8346232
41. Bickel PJ, Cosman PC, Olshen RA, Spector PC, Rodrigo AG, et al. (2009) Covariability of V3 Loop Amino Acids.
42. Wang Q, Lee C, (2007) Distinguishing functional amino acid covariation from background linkage disequilibrium in HIV protease and reverse transcriptase. PLoS One 2: e814. doi: 10.1371/journal.pone.0000814 17726544
43. Caporaso JG, Smit S, Easton BC, Hunter L, Huttley GA, et al. (2008) Detecting coevolution without phylogenetic trees? Tree-ignorant metrics of coevolution perform as well as tree-aware metrics. BMC Evol Biol 8: 327. doi: 10.1186/1471-2148-8-327 19055758
44. Poon AFY, Swenson LC, Dong WWY, Deng W, Kosakovsky Pond SL, et al. (2010) Phylogenetic analysis of population-based and deep sequencing data to identify coevolving sites in the nef gene of HIV-1. Mol Biol Evol 27: 819–832. doi: 10.1093/molbev/msp289 19955476
45. Pond SLK, Frost SDW, Muse S V, (2005) HyPhy: hypothesis testing using phylogenies. Bioinformatics 21: 676–679. doi: 10.1093/bioinformatics/bti079 15509596
46. Doolittle RF, (1994) Convergent evolution: the need to be explicit. Trends Biochem Sci 19: 15–18. doi: 10.1016/0968-0004(94)90167-8 8140615
47. Felsenstein J, (1978) Cases in which Parsimony or Compatibility Methods will be Positively Misleading. Syst Biol 27: 401–410. doi: 10.1093/sysbio/27.4.401
48. Lemey P, Derdelinckx I, Rambaut A, Van Laethem K, Dumont S, et al. (2005) Molecular footprint of drug-selective pressure in a human immunodeficiency virus transmission chain. J Virol 79: 11981–11989. doi: 10.1128/JVI.79.18.11981-11989.2005 16140774
49. Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, et al. (2012) Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog 8: e1002529. doi: 10.1371/journal.ppat.1002529 22412369
50. Myint L, Matsuda M, Matsuda Z, Chiba T, Okano A, et al. (2004) Gag Non-Cleavage Site Mutations Contribute to Full Recovery of Viral Fitness in Protease Inhibitor-Resistant Human Immunodeficiency Virus Type 1 Gag Non-Cleavage Site Mutations Contribute to Full Recovery of Viral Fitness in Protease Inhibitor-Resistant H. Antimicrob Agents Chemother 48: 444–452. doi: 10.1128/AAC.48.2.444 14742193
51. Aoki M, Venzon DJ, Koh Y, Aoki-Ogata H, Miyakawa T, et al. (2009) Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors. J Virol 83: 3059–3068. doi: 10.1128/JVI.02539-08 19176623
52. Breuer S, Sepulveda H, Chen Y, Trotter J, Torbett BE, (2011) A cleavage enzyme-cytometric bead array provides biochemical profiling of resistance mutations in HIV-1 Gag and protease. Biochemistry 50: 4371–4381. doi: 10.1021/bi200031m 21452835
53. Lee S-K, Potempa M, Kolli M, Özen A, Schiffer CA, et al. (2012) Context surrounding processing sites is crucial in determining cleavage rate of a subset of processing sites in HIV-1 Gag and Gag-Pro-Pol polyprotein precursors by viral protease. J Biol Chem 287: 13279–13290. doi: 10.1074/jbc.M112.339374 22334652
54. Carlson JM, Brumme ZL, Rousseau CM, Brumme CJ, Matthews P, et al. (2008) Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. PLoS Comput Biol 4: e1000225. doi: 10.1371/journal.pcbi.1000225 19023406
55. Gilbert PB, Novitsky V, Essex M, (2005) Covariability of selected amino acid positions for HIV type 1 subtypes C and B. AIDS Res Hum Retroviruses 21: 1016–1030. doi: 10.1089/aid.2005.21.1016 16379605
56. Rolland M, Carlson JM, Manocheewa S, Swain JV, Lanxon-Cookson E, et al. (2010) Amino-acid co-variation in HIV-1 Gag subtype C: HLA-mediated selection pressure and compensatory dynamics. PLoS One 5: 10. doi: 10.1371/journal.pone.0012463
57. Dahirel V, Shekhar K, Pereyra F, Miura T, Artyomov M, et al. (2011) Coordinate linkage of HIV evolution reveals regions of immunological vulnerability. Proc Natl Acad Sci U S A 108: 11530–11535. doi: 10.1073/pnas.1105315108 21690407
58. Kalinina O V, Oberwinkler H, Glass B, Kräusslich H- G, Russell RB, et al. (2012) Computational identification of novel amino-acid interactions in HIV Gag via correlated evolution. PLoS One 7: e42468. doi: 10.1371/journal.pone.0042468 22879995
59. Weigt M, White RA, Szurmant H, Hoch JA, Hwa T, (2009) Identification of direct residue contacts in protein-protein interaction by message passing. Proc Natl Acad Sci U S A 106: 67–72. doi: 10.1073/pnas.0805923106 19116270
60. Morcos F, Jana B, Hwa T, Onuchic JN, (2013) Coevolutionary signals across protein lineages help capture multiple protein conformations. Proc Natl Acad Sci U S A 110: 20533–20538. doi: 10.1073/pnas.1315625110 24297889
61. Sulkowska JI, Morcos F, Weigt M, Hwa T, Onuchic JN, (2012) Genomics-aided structure prediction. PNAS 109: 10340–10345. doi: 10.1073/pnas.1207864109 22691493
62. Haq O, Andrec M, Morozov A V, Levy RM, (2012) Correlated electrostatic mutations provide a reservoir of stability in HIV protease. PLoS Comput Biol 8: e1002675. doi: 10.1371/journal.pcbi.1002675 22969420
63. Mann JK, Barton JP, Ferguson AL, Omarjee S, Walker BD, et al. (2014) The Fitness Landscape of HIV-1 Gag: Advanced Modeling Approaches and Validation of Model Predictions by In Vitro Testing. PloS Comput Biol 10(8): e1003776. doi: 10.1371/journal.pcbi.1003776 25102049
64. Kang S, (1999) An optimal property of the exact multinomial test and the extended Fisher’s exact test. Stat Probab Lett 44: 201–207. doi: 10.1016/S0167-7152(99)00010-3
65. Dunn SD, Wahl LM, Gloor GB, (2008) Mutual information without the influence of phylogeny or entropy dramatically improves residue contact prediction. Bioinformatics 24: 333–340. doi: 10.1093/bioinformatics/btm604 18057019
66. Dutheil JY, (2012) Detecting coevolving positions in a molecule: why and how to account for phylogeny. Brief Bioinform 13: 228–243. doi: 10.1093/bib/bbr048 21949241